131 related articles for article (PubMed ID: 8579116)
1. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas.
Kauppila S; Saarela J; Stenbäck F; Risteli J; Kauppila A; Risteli L
Am J Pathol; 1996 Feb; 148(2):539-48. PubMed ID: 8579116
[TBL] [Abstract][Full Text] [Related]
2. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
Zhu GG; Risteli J; Puistola U; Kauppila A; Risteli L
Cancer Res; 1993 Oct; 53(20):5028-32. PubMed ID: 8402695
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
4. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.
Autio-Harmainen H; Karttunen T; Hurskainen T; Höyhtyä M; Kauppila A; Tryggvason K
Lab Invest; 1993 Sep; 69(3):312-21. PubMed ID: 8377473
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
6. [Expression of type I and type III procollagen genes in human scirrhous carcinoma of breast by in situ hybridization].
Gan YB
Zhonghua Zhong Liu Za Zhi; 1992 Sep; 14(5):348-50. PubMed ID: 1337890
[TBL] [Abstract][Full Text] [Related]
7. Aberrant type I and type III collagen gene expression in human breast cancer in vivo.
Kauppila S; Stenbäck F; Risteli J; Jukkola A; Risteli L
J Pathol; 1998 Nov; 186(3):262-8. PubMed ID: 10211114
[TBL] [Abstract][Full Text] [Related]
8. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
9. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
10. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
11. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
12. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
13. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
14. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
[TBL] [Abstract][Full Text] [Related]
16. Differential localization of type I and type III procollagen messenger ribonucleic acids in inflamed periodontal and periapical connective tissues by in situ hybridization.
Larjava H; Sandberg M; Happonen RP; Vuorio E
Lab Invest; 1990 Jan; 62(1):96-103. PubMed ID: 2296161
[TBL] [Abstract][Full Text] [Related]
17. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
18. Dermal fibroblasts from different layers of human skin are heterogeneous in expression of collagenase and types I and III procollagen mRNA.
Ali-Bahar M; Bauer B; Tredget EE; Ghahary A
Wound Repair Regen; 2004; 12(2):175-82. PubMed ID: 15086769
[TBL] [Abstract][Full Text] [Related]
19. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix.
Wu M; Gunning W; Ratnam M
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):775-82. PubMed ID: 10498396
[TBL] [Abstract][Full Text] [Related]
20. Expression of Fas and FasL in human serous ovarian epithelial tumors.
van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
